A larger dental network should be evaluated through operational consistency and clearly assigned clinical responsibility, alongside financial growth.
Funding behind the consumer brand
MakeO, parent of dental aligner brand Toothsi, has raised ₹90 crore in a round led by Singularity AMC, according to October 13 reporting from The Economic Times and Inc42. Both name DSP family office, Genesis and Unispace Ventures among participants. The reports describe a completed raise, not a future funding target.
The Economic Times links the capital to manufacturing and technology facilities, integration following the Zenyum acquisition and offline clinic expansion. Inc42 also reports spending plans for manufacturing, clinical centres and backend technology. We use the corroborated rupee amount rather than introduce a less consistent dollar conversion from discovery coverage.
The funding announcement is a business story. It does not establish that any treatment is appropriate for an individual or that a larger network produces superior clinical results. We have not tested MakeO’s products or independently audited patient outcomes. The analysis here concerns the operational structure behind expansion.
A network is not the same as a clinic count
Inc42 reports that MakeO says its combined network includes around 1,100 partner dentists across ten countries and more than 60 offline clinical centres. Those are company-reported reach figures, not independently audited counts or evidence of treatment outcomes.
The distinction between partner dentists and centres is useful. They describe different ways a brand can reach a customer, and should not be added together as though they were equivalent locations. A network footprint also does not establish how much activity occurs at each point.
Our interpretation is that connecting that footprint with manufacturing and technology is the operating task behind the funding. The brand can provide a common entry point while the provider retains responsibility for clinical decisions. Expanding the commercial network does not remove that boundary.
An analytical map of a dental network
Clinic
A qualified provider assesses and owns the clinical decision.
Production
The prescribed product moves through manufacturing and quality processes.
Delivery
The clinic and patient receive clear information and follow-up arrangements.
Feedback
Operational issues return to the responsible team for resolution.
The integration spend has a specific purpose
The Economic Times identifies integration following the Zenyum acquisition among the capital uses. Alongside manufacturing investment and clinic expansion, that makes the round more than a plan to open additional centres.
Information must move between the prescribed product, the production record and the responsible clinic. A shared interface could help, but the organisation still needs an unambiguous owner for each handoff. That is an analytical coordination requirement, not a finding of an existing defect.
The ₹90 crore gives MakeO resources for several parts of that connected operation. The customer ultimately encounters the connection when the appropriate product and information reach the treating provider. That is where a wider network has to become a coherent service, with commercial and clinical responsibilities kept clear.
Sources
- MakeO raises ₹90 crore for India and Southeast Asia expansion ↗ Inc42 · 2026-10-13
- Toothsi parent MakeO raises ₹90 crore for dental care expansion ↗ The Economic Times · 2026-10-13
Have additional information? Request a correction.
